News for Emergent BioSolutions Inc. (0IGA.L)

Here is a list of companies that announced the most significant buybacks as a percentage of their market caps.

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS stock as a sell.

GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (:EBS), a leading public health company that delivers protective and life-sav

**media[572510]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada LONDON and

**media[571897,571898]**

Emergent BioSolutions will lead commercial launch efforts to increase access to intranasal naloxone and combat opioid overdose poisonings in Canada

Despite announcing the completion of its first biologics site acquisition in the US, Syngene, the contract research arm of Biocon, saw its shares dip 0.42% at Rs 703.10 on the BSE as of 10:35 AM in intraday trading.

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (:EBS) today announced that it has completed the sale of its Baltimore-Bayvie

GAITHERSBURG, Md., March 18, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (: EBS) today announced it has recently secured approximately $27 million in

NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings on how

**media[565590]**

Stocks in news: IndusInd Bank, Hindustan Zinc, IIFL Finance, BEL, NTPC and more

PR NewswireBANGALORE, India, March 10, 2025 Expected to enhance global innovator flexibility with biologics drug substance facility in BaltimoreBANGALORE,

**media[562046]**

California-based GigaCloud Technology Inc. (GCT) is down over 21 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Total Revenue (Q4 2024): $195 million, down from the prior year.Adjusted EBITDA (Q4 2024): $21 million, an increase of $18 million year-over-year.Adjusted Gros

Mar 03, 2025 / 10:00PM GMTOperator Good day and thank you for standing by. Welcome to Merchant buyer Solutions Inc. fourth quarter 2024 earnings conference call

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ETCompany ParticipantsFrank Vargo - Assistant TreasurerJoseph...